38 CFR Ch. I (7-1-13 Edition)

§4.117		38 CFR Ch. I (7-1-13 Ec	dition)
	Rating		Rating
Vaginal fecal leakage one to three times per week requiring wearing of pad Vaginal fecal leakage less than once a week	30 10 0 100 60 40 20 180 150 160 140	Note: A rating of 100 percent shall continue beyond the cessation of any surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter. If there has been no local recurrence or metastasis, rate on residuals. 7628 Benign neoplasms of the gynecological system or breast. Rate according to impairment in function of the urinary or gynecological systems, or skin. 7629 Endometriosis: Lesions involving bowel or bladder confirmed by laparoscopy, pelvic pain or heavy or irregular bleeding not controlled by treatment, and bowel or bladder symptoms Pelvic pain or heavy or irregular bleeding not controlled by treatment. Pelvic pain or heavy or irregular bleeding requiring continuous treatment for control Note: Diagnosis of endometriosis must be substantiated by laparoscopy. 1 Review for entitlement to special monthly compunder §3.350 of this chapter. [60 FR 19855, Apr. 21, 1995, as amended FR 6874, Feb. 14, 2002; 67 FR 37695, M. 2002] THE HEMIC AND LYMPHATIC SYST	50 30 10 Densation d at 67 Iay 30,
(2) Modified radical mastectomy means removal of the entire breast and axillary lymph nodes		lymphatic systems.	Rating
(in continuity with the breast). Pectoral muscles are left intact (3) Simple (or total) mastectomy		7700 Anemia, hypochromic-microcytic and megaloblastic, such as iron-deficiency and per-	Rating
means removal of all of the breast tissue, nipple, and a small portion of the overlying skin, but lymph nodes and muscles are left intact (4) Wide local excision (including partial mastectomy,		nicious anemia: Hemoglobin 5gm/100ml or less, with findings such as high output congestive heart failure or dyspnea at rest Hemoglobin 7gm/100ml or less, with findings such as dyspnea on mild exertion, cardiomegaly, tachycardia (100 to 120	100
lumpectomy, tylectomy, segmentectomy, and quadrantectomy) means removal of a portion of the breast tissue		beats per minute) or syncope (three epi- sodes in the last six months)	70
7627 Malignant neoplasms of gynecological sys-		headaches, lightheadedness, or short- ness of breath	30

hemic and

		Rating
meg	Anemia, hypochromic-microcytic and paloblastic, such as iron-deficiency and per-	
	Hemoglobin 5gm/100ml or less, with find- ings such as high output congestive heart failure or dyspnea at rest	100
	Hemoglobin 7gm/100ml or less, with find- ings such as dyspnea on mild exertion, cardiomegaly, tachycardia (100 to 120 beats per minute) or syncope (three epi-	
	sodes in the last six months) Hemoglobin 8gm/100ml or less, with find- ings such as weakness, easy fatigability,	70
	headaches, lightheadedness, or short- ness of breath	30
	ings such as weakness, easy fatigability or headaches	10
	tomatic	0
	Evaluate complications of pernicious anemia, sentia or peripheral neuropathy, separately.	such as
7702	Agranulocytosis, acute: Requiring bone marrow transplant, or; requiring transfusion of platelets or red cells at least once every six weeks, or;	

100

7627 Malignant neoplasms of gynecological system or breast

Ş	4.	1	1	8

Requiring transfusion of platelets or red cells at least once every three months, or; infections recurring at least once
every three months
Requiring continuous medication for control
NOTE: The 100 percent rating for bone marrow tra shall be assigned as of the date of hospital admissi shall continue with a mandatory VA examinati months following hospital discharge. Any change i uation based upon that or any subsequent examball be subject to the provisions of §3.105(e) chapter.
703 Leukemia: With active disease or during a treatment
phase
NOTE: The 100 percent rating shall continue beyond the sation of any surgical, radiation, antineoplastic of therapy or other therapeutic procedures. Six month
discontinuance of such treatment, the appropriate di rating shall be determined by mandatory VA exam Any change in evaluation based upon that or any quent examination shall be subject to the provis §3.105(e) of this chapter. If there has been no recu rate on residuals.
704 Polycythemia vera: During periods of treatment with
myelosuppressants and for three months following cessation of myelosuppressant
therapy Requiring phlebotomy Stable, with or without continuous medication
NOTE: Rate complications such as hypertension, gout, or thrombotic disease separately.
705 Thrombocytopenia, primary, idiopathic or immune:
Platelet count of less than 20,000, with active bleeding, requiring treatment with
Platelet count between 20,000 and 70,000,
not requiring treatment, without bleeding Stable platelet count between 70,000 and
100,000, without bleeding
Stable platelet count of 100,000 or more, without bleeding
706 Splenectomy
NOTE: Rate complications such as systemic infection encapsulated bacteria separately.
initian siu

With active disease or during a treatment

7707 Spleen, injury of, healed.

Rate for any residuals. 7709 Hodgkin's disease:

		Rating
7710	Adenitis, tuberculous, active or inactive. Rate under §§ 4.88c or 4.89 of this part, whichever is appropriate.	
7714	Sickle cell anemia: With repeated painful crises, occurring in skin, joints, bones or any major organs caused by hemolysis and sickling of red blood cells, with anemia, thrombosis and infarction, with symptoms precluding	
	even light manual labor	100
	light manual laborFollowing repeated hemolytic sickling cri-	60
	ses with continuing impairment of health Asymptomatic, established case in remis- sion, but with identifiable organ impair-	30
	ment	10

NOTE: Sickle cell trait alone, without a history of directly attributable pathological findings, is not a ratable disability. Cases of symptomatic sickle cell trait will be forwarded to the Director, Compensation and Pension Service, for consideration under § 3.321(b)(1) of this chapter.

IOTE: The 100 percent rating shall continue beyond the cessation of any surgical, radiation, antineoplastic chemotherapy or other therapeutic procedures. Six months after discontinuance of such treatment, the appropriate disability rating shall be dtermined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter. If there has been no local recurrence or metastasis, rate on residuals.

716 Aplastic anemia:

Requiring bone marrow transplant, or; requiring transfusion of platelets or red cells at least once every six weeks, or; infections recurring at least once every six weeks 100 Requiring transfusion of platelets or red cells at least once every three months, or; infections recurring at least once every three months 60 Requiring transfusion of platelets or red cells at least once per year but less than once every three months, or; infections recurring at least once per year but less than once every three months 30 Requiring continuous medication for control 10

NOTE: The 100 percent rating for bone marrow transplant shall be assigned as of the date of hospital admission and shall continue with a mandatory VA examination six months following hospital discharge. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter.

7717 AL amyloidosis (primary amyloidosis) 100

[60 FR 49227, Sept. 22, 1995, as amended at 77 FR 6467, Feb. 8, 2012]

THE SKIN

§ 4.118 Schedule of ratings—skin.

A veteran whose scars were rated by VA under a prior version of diagnostic codes 7800, 7801, 7802, 7803, 7804, or 7805,